SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law

Non-Compliance Means Nasdaq De-Listing In 2024

 
• By Mandy Jackson
Stock market chart with US and China flag overlays
US-listed Chinese companies face accounting firm scrutiny • Source: Alamy

More from Financing

More from Business